Entering text into the input field will update the search result below

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript

Mar. 09, 2020 11:06 AM ETBioXcel Therapeutics, Inc. (BTAI)
SA Transcripts profile picture
SA Transcripts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2019 Earnings Conference Call March 9, 2020 8:30 AM ET

Company Participants

Vimal Mehta - Founder and CEO

Richard Steinhart - VP and CFO

Frank Yocca - SVP and Chief Scientific Officer

Vincent O'Neill - SVP and Chief Medical Officer

Rob Risinger - VP, Clinical Development

Conference Call Participants

Robyn Karnauskas - SunTrust Robinson Humphrey

Sumant Kulkarni - Canaccord Genuity

Do Kim - BMO Capital Markets

Raghuram Selvaraju - H.C. Wainwright


Good morning, and welcome to BioXcel Therapeutics' Fourth Quarter and Full-Year 2019 Earnings Conference Call and audio webcast. Before we start, I would like to inform that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open up the conference for questions-and-answers after the presentation. [Operator Instructions]

Just to remind everyone, certain matters discussed in today's conference call or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties relating to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect results are detailed in the company's most recent public filings with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2019, which can be found on the Web site www.bioxceltherapeutics.com or on www.sec.gov.

I would now like to turn the call over to Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics. Please go ahead.

Vimal Mehta

Thank you, Operator. Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the fourth quarter and full-year of 2019. We appreciate everyone's time and attention today. 2019 has proven to be

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.